By CapitalSnitch Research Desk · updated Oct 11, 2026 · data from SEC filings and official Congress disclosures
Pacira BioSciences, Inc. executives and directors have only been selling lately: five insiders unloaded about $2.8 million of stock over 12 months, with no open-market purchases.
Selling on its own is common and often pre-planned (10b5-1 plans, taxes, diversification), so it matters more when it is unusually heavy or broad.
Zooming out by quarter: 7 quarters in a row of net selling by insiders. Insiders bought in 0 of the last 7 full quarters. 253 investment managers listed PCRX in their latest 13F filings (Q2 2026); funds were split between buying and selling.
Are insiders buying or selling PCRX stock?
In the last 12 months Pacira BioSciences, Inc. insiders made open-market purchases worth about $0 and sales worth about $2.8 million. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
When was the last insider trade in PCRX?
The most recent open-market insider trade in PCRX was filed on 2026-10-09.
How many institutions own PCRX?
253 investment managers reported holding PCRX in SEC Form 13F filings for Q2 2026.
Has any member of Congress traded PCRX?
No congressional trades in PCRX were reported in the past two years. The full list is free on CapitalSnitch.
Free weekly email: the week's biggest insider buys and Congress trades, every Monday. No spam, one-click unsubscribe.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1).
Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).